|
[이데일리TV 이혜라 기자] On the 5th, E-Daily TV’s Big Money Part 1’News in Issue’ looked at Phoebe Pharma (Prestige Bio Pharma), which was listed on the stock market.
Is a Singapore-based biosimilar and antibody drug developer established in 2015. Last month, it was listed on the KOSPI by successively winning success in demand forecasting and general subscription conducted for institutional and individual investors.
Phoebe Pharma puts out specialized technology that can secure’price competitiveness’ as its strength. The biosimilar (HD201) of Herceptin, a breast cancer drug, is about to be released in Europe. In addition, the pancreatic cancer target antibody treatment (PBP1510), designated as an orphan drug by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Korea Food and Drug Administration last year, is highly likely to become a blockbuster new drug when the development is completed.
Park So-yeon, CEO of PB Pharma, said, “We aim to enter the world’s top 10 in the biosimilar/antibody drug development industry within the next 10 years.”
What kind of company is Phoebe Pharma listed today?
-Biosimilar/antibody drug development company
-The first foreign bio company to be listed on KOSPI
-Demand forecasting and general subscription are both’box-box’
First case of Singapore company listed on KOSPI?
-Foreign company established in Singapore in 2015
-Composed of representatives and executives, domestic researchers
-“Korea, bio company value evaluation favorable”
How competitive is this company?
-‘Price competitiveness’ strength… Secure specialized technology
-Pancreatic cancer target antibody treatment (PBP1510)… Orphan drug designation
-Breast cancer treatment Herceptin biosimilar ahead of European launch
What are your listing background and goals?
-So-yeon Park, CEO, “Aim to become the top 10 global antibody company”
[인터뷰: 박소연 대표 / 피비파마(프레스티지바이오파마)]
“The goal is to quickly enter the clinical stage of many biosimilars being developed and put them on the market quickly. New therapeutic targets such as PAUF and CTHRC1 are being developed. So, based on this innovative platform technology, we plan to focus on developing new antibody drugs.”